Texas Permanent School Fund I Teos Therapeutics, Inc. Transaction History

Texas Permanent School Fund

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$10.95 - $14.6 $7,336 - $9,782	670 Added 3.13%	22,109 $242,000
Q2 2023 Aug 07, 2023	SELL	$12.93 - $18.05 $3,814 - $5,324	-295 Reduced 1.36%	21,439 $283,000
Q1 2023 May 01, 2023	BUY	$13.02 - $22.62 $68,120 - $118,347	5,232 Added 31.71%	21,734 $295,000
Q4 2022 Feb 07, 2023	SELL	$17.77 - $21.6 $20,524 - $24,948	-1,155 Reduced 6.54%	16,502 $322,000
Q3 2022 Oct 25, 2022	BUY	$18.6 - $27.25 $56,079 - $82,158	3,015 Added 20.59%	17,657 $336,000
Q2 2022 Aug 08, 2022	BUY	$16.57 - $35.1 $6,429 - $13,618	388 Added 2.72%	14,642 $302,000
Q1 2022 May 06, 2022	BUY	$31.92 - $47.45 $454,987 - $676,352	14,254 New	14,254 $459,000

165

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $293M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

Stay updated on Texas Permanent School Fund with notifications on news.